Several analysts have recently updated their ratings and price targets for Novartis AG (VTX: NOVN):

  • 7/7/2017 – Novartis AG was given a new CHF 80 price target on by analysts at Deutsche Bank AG. They now have a “neutral” rating on the stock.
  • 7/5/2017 – Novartis AG was given a new CHF 77 price target on by analysts at Credit Suisse Group. They now have a “sell” rating on the stock.
  • 7/4/2017 – Novartis AG was given a new CHF 88 price target on by analysts at Kepler Capital Markets. They now have a “buy” rating on the stock.
  • 6/23/2017 – Novartis AG was given a new CHF 103 price target on by analysts at Jefferies Group LLC. They now have a “buy” rating on the stock.
  • 6/23/2017 – Novartis AG was given a new CHF 80 price target on by analysts at Barclays PLC. They now have a “neutral” rating on the stock.
  • 6/21/2017 – Novartis AG was given a new CHF 78 price target on by analysts at Deutsche Bank AG. They now have a “neutral” rating on the stock.
  • 6/21/2017 – Novartis AG was given a new CHF 85 price target on by analysts at HSBC Holdings plc. They now have a “buy” rating on the stock.
  • 6/21/2017 – Novartis AG was given a new CHF 80 price target on by analysts at Goldman Sachs Group, Inc. (The). They now have a “neutral” rating on the stock.
  • 6/14/2017 – Novartis AG was given a new CHF 80 price target on by analysts at Goldman Sachs Group, Inc. (The). They now have a “neutral” rating on the stock.
  • 6/5/2017 – Novartis AG was given a new CHF 100 price target on by analysts at Jefferies Group LLC. They now have a “buy” rating on the stock.
  • 6/2/2017 – Novartis AG was given a new CHF 80 price target on by analysts at Goldman Sachs Group, Inc. (The). They now have a “neutral” rating on the stock.
  • 6/2/2017 – Novartis AG was given a new CHF 65 price target on by analysts at Barclays PLC. They now have a “sell” rating on the stock.
  • 5/29/2017 – Novartis AG was given a new CHF 100 price target on by analysts at Jefferies Group LLC. They now have a “buy” rating on the stock.
  • 5/29/2017 – Novartis AG was given a new CHF 75 price target on by analysts at Morgan Stanley. They now have a “sell” rating on the stock.
  • 5/20/2017 – Novartis AG was given a new CHF 100 price target on by analysts at Jefferies Group LLC. They now have a “buy” rating on the stock.
  • 5/20/2017 – Novartis AG was given a new CHF 75 price target on by analysts at Morgan Stanley. They now have a “sell” rating on the stock.
  • 5/20/2017 – Novartis AG was given a new CHF 70 price target on by analysts at J P Morgan Chase & Co. They now have a “neutral” rating on the stock.
  • 5/20/2017 – Novartis AG was given a new CHF 80 price target on by analysts at Goldman Sachs Group, Inc. (The). They now have a “neutral” rating on the stock.

Novartis AG (NOVN) traded down 0.88% during mid-day trading on Tuesday, reaching CHK 78.80. 3,691,688 shares of the company’s stock traded hands. The firm has a 50 day moving average of CHK 79.68 and a 200 day moving average of CHK 75.84. Novartis AG has a 1-year low of CHK 67.40 and a 1-year high of CHK 84.35.

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.